Devyser Diagnostics
129
SEK
-1.9 %
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
2 following
-1.9%
0%
+21.13%
+29.52%
+64.12%
+98.46%
-
-
+44.94%
investors.devyser.com/en
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Revenue
169.3M
EBIT %
-34.79 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DVYSR
Daily low / high price
127 / 131.5
SEK
Market cap
2.13B SEK
Turnover
10.31M SEK
Volume
80K
Latest videos
Financial calendar
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Rutger Arnhult, via bolag | 24.5 % | 24.5 % |
| Nordnet Pensionsförsäkringar | 10.6 % | 10.6 % |
| Swedbank Robur | 6.5 % | 6.5 % |
| Fjärde AP-fonden | 4.6 % | 4.6 % |
| Stockholm Pacific AB, Åsa Riisberg | 4.0 % | 4.0 % |
| Berenberg Asset Management på uppdrag av Universal Investment funds | 3.8 % | 3.8 % |
| Anders Hedrum, privat och via bolag | 2.5 % | 2.5 % |
| Deka Investements | 2.5 % | 2.5 % |
| Insr Insurance Group | 2.3 % | 2.3 % |
| Protean Funds | 2.2 % | 2.2 % |
ShowingAll content types
Nomination Committee Appointed Ahead of the 2025 Annual General Meeting in Devyser Diagnostics AB
Redeye: Devyser Q3 - All eyes on Q4
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Devyser Diagnostics, Audiocast with teleconference, Q3'24
Devyser Diagnostics AB publishes quarterly report for the period July to September 2024
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoring
Devyser Compact achieves Class III approval in China
Invitation to Devyser’s Capital Markets Day
Invitation to audiocast for Devyser’s Q3 report 2024
Devyser terminates liquidity guarantee agreement
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation
Redeye: Devyser Diagnostics - Sticky business worthy of a premium
Redeye: Devyser Diagnostics Q2 - Entering a potentially case altering phase
